C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter A—GeneralPart 7—Enforcement PolicySubpart C—Recalls (Including Product Corrections)—Guidance on Policy, Procedures, and Industry Responsibilities

21 C.F.R. § 7.40 (2026)

Recall policy

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1981–2024 18citing cases
At a glance

Courts have cited this section in 18 opinions since 1981, 2 of them in the last five years. The most litigated part is subsection (a) (1 case).

(a) Recall is an effective method of removing or correcting consumer products that are in violation of laws administered by the Food and Drug Administration. Recall is a voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective. This section and §§ 7.41 through 7.59 recognize the voluntary nature of recall by providing guidance so that responsible firms may effectively discharge their recall responsibilities. These sections also recognize that recall is an alternative to a Food and Drug Administration-initiated court action for removing or correcting violative, distributed products by setting forth specific recall procedures for the Food and Drug Administration to monitor recalls and assess the adequacy of a firm's efforts in recall.

(b) Recall may be undertaken voluntarily and at any time by manufacturers and distributors, or at the request of the Food and Drug Administration. A request by the Food and Drug Administration that a firm recall a product is reserved for urgent situations and is to be directed to the firm that has primary responsibility for the manufacture and marketing of the product that is to be recalled.

(c) Recall is generally more appropriate and affords better protection for consumers than seizure, when many lots of product have been widely distributed. Seizure, multiple seizure, or other court action is indicated when a firm refuses to undertake a recall requested by the Food and Drug Administration, or where the agency has reason to believe that a recall would not be effective, determines that a recall is ineffective, or discovers that a violation is continuing.

[43 FR 26218, June 16, 1978, as amended at 65 FR 56476, Sept. 19, 2000]
The 18 cases that cite 21 C.F.R. § 7.40 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENGross v. Stryker Corp., 858 F. Supp. 2d 466 (W.D. Pa. 2012).
cites § 7.40 2×cited by 39 cases
Where it cites § 7.40
“” 21 C.F.R. § 7.40 . Furthermore, a manufacturer may initiate a recall “because it believes the product to be violative.”
The case’s holding
A claim for breach of express warranty is insufficiently pled without alleging a specific promise or affirmative statement made by the defendant.
Later courts cite it for
“absent a demonstration that a promise or affirmative statement was made, how or by whom the promise was made, or what was in fact promised, a claim for breach of express warranty is not sufficiently plead.” · 4 citing courts
2
GREENIn re Medtronic, Inc. Sprint Fidelis Leads Prods. Liab. Litig., 592 F. Supp. 2d 1147 (D. Minn. 2009).
cites § 7.40 1×cited by 84 cases
Where it cites § 7.40
“21 C.F.R. § 7.40 (a). Yet, there would be no reason to invalidate the device's PMA — if the assembly error were corrected, then the device could (and would) be manufactured according to the FDA-approved PMA specifications.”
The case’s holding
State-law claims are preempted if they impose requirements different from or in addition to federal requirements established through the pre-market approval process for medical devices.
Later courts cite it for
“an adequately pleaded claim that a specific device was not manufactured in accordance with its pma specifications can survive preemption.” · 3 citing courts
3
GREENRule v. Fort Dodge Animal Health, Inc., 607 F.3d 250 (1st Cir. 2010).
cites § 7.40 1×cited by 52 cases
Where it cites § 7.40
“See 21 C.F.R. § 7.40 (2009). But the unfitness of ProHeart 6 lay in its potential for causing harm to the dog.”
The case’s holding
Injury under the Massachusetts consumer protection statute requires traditional economic injury, such as actual financial loss or the diminished value of a retained product.
Later courts cite it for
“have returned to the notion that injury under chapter 93a means economic injury in the traditional sense.” · 9 citing courts
4
GREENNetherlands Ins. Co. v. Main Street Ingredients, LLC, 745 F.3d 909 (8th Cir. 2014).
cites § 7.40 1×cited by 44 cases
Where it cites § 7.40
“See also 21 C.F.R. § 7.40 (a) ("Recall is an effective method of removing or correcting consumer products that are in violation of laws administered by the Food and Drug Administration.”
The case’s holding
A settlement triggers indemnity if the insured could have been liable on the facts and a product rendered unsaleable by regulation suffers physical injury.
Later courts cite it for
“because the parties do not dispute the choice of minnesota law, we assume, without deciding, minnesota law applies . . . .” · 18 citing courts
5
GREENJones v. Conagra Foods, Inc., 912 F. Supp. 2d 889 (N.D. Cal. 2012).
cites § 7.40 1×cited by 38 cases
Where it cites § 7.40
“§ 332 ; 21 C.F.R. § 7.40 . In 1990, Congress passed the NLEA to specifically address certain food and beverage labeling requirements, such as requiring the identification of artificial flavors on the label, 21 U.”
The case’s holding
Whether a product label is deceptive is a question for the courts, and a plaintiff who would not have bought a mislabeled product has sufficiently alleged injury under California consumer laws.
Later courts cite it for
“reasonable-consumer determination and other issues involved in plaintiffs lawsuit are within the expertise of the courts to resolve.” · 4 citing courts
6
GREENLockwood v. Conagra Foods, Inc., 597 F. Supp. 2d 1028 (N.D. Cal. 2009).
cites § 7.40 1×cited by 29 cases
Where it cites § 7.40
“The purpose of the NLEA was to “ ‘clarify and to strengthen [FDA’s] authority to require nutrition labeling on foods, and to establish the circumstances under which claims may be made about the nutrients in foods.”
The case’s holding
Consumer-protection claims challenging a food's labeling as misleading are not preempted by federal food-labeling law where the labeling falls outside federally regulated areas, since courts can decide whether conduct is misleading.
Later courts cite it for
“gives the fda the responsibility to protect the public health by ensuring that 'foods are safe, wholesome, sanitary, and properly labeled.” · 5 citing courts
7
GREENSteven Recht v. Patrick Morrisey, 32 F.4th 398 (4th Cir. 2022).
cites § 7.40 1×cited by 11 cases
Where it cites § 7.40
“or at the request of the [FDA],” 21 C.F.R. § 7.40 (a)–(b), plaintiffs conclude that the Act bans the use of the word “recall” in this situation.”
8
GREENBanfi Prods. Corp. v. United States, 40 Fed. Cl. 107 (Fed. Cl. 1997).
cites § 7.40 2×cited by 10 cases
Where it cites § 7.40
“21 C.F.R. § 7.40 . According to the language of the final rule, the regulations were intended as “guidelines.”
9
GREENClark v. Actavis Grp. HF, 567 F. Supp. 2d 711 (D.N.J. 2008).
cites § 7.40 3×cited by 3 cases
Where it cites § 7.40
“2d at 432 (citing 21 C.F.R. § 7.40 (a)). “These regulations set forth specific recall procedures whereby the FDA assumes control over monitoring recalls and assesses the adequacy of a firm’s efforts in undertaking the recall.”
10
GREENWash. Cnty. Health Care Auth., Inc. v. Baxter Int'l Inc., 328 F. Supp. 3d 824 (E.D. Ill. 2018).
cites § 7.40 1×cited by 5 cases
Where it cites § 7.40
“§ 331 (a) (prohibiting "the introduction or delivery for introduction into interstate commerce of any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded"); see also 21 C.F.R. § 7.40 (noting that "recall is an alternative to a Food and Drug…”
11
GREENUnited States v. Superpharm Corp., 530 F. Supp. 408 (E.D.N.Y. 1981).
cites § 7.40 3×cited by 4 cases
Where it cites § 7.40
“While there are provisions in the FDA regulations which provide for recalls, recalls cannot be ordered by the FDA, see 21 CFR § 7.40 (a), as they are usually undertaken voluntarily, 21 CFR § 7.”
12
GREENHolk v. Snapple Beverage Corp., 574 F. Supp. 2d 447 (D.N.J. 2008).
cites § 7.40 2×cited by 2 cases
Where it cites § 7.40
“§ 332 ; 21 C.F.R. § 7.40 . The FDA has promulgated comprehensive regulations pursuant to its authority under the FFDCA.”
13
GREENIn re Human Tissue Prods. Liab. Litig., 488 F. Supp. 2d 430 (D.N.J. 2007).
cites § 7.40 1×cited by 2 cases
Where it cites § 7.40
“See 21 C.F.R. § 7.40 (a). These regulations set forth specific recall procedures whereby the FDA assumes control over monitoring recalls and assesses the adequacy of a firm’s efforts in undertaking the recall.”
Later courts cite it for
“possessed the authority to order this notice under its 'inherent powers' and its ability to manage complex multidistrict litigation.” · 1 citing court
14
NO FLAGAlison Beavan v. Allergan U.S.A., Inc., No. A-1501-23 (N.J. Super. Ct. App. Div. Nov. 21, 2024).
cites § 7.40 5×cited by 0 casesunpublished
Where it cites § 7.40
“Defendant argues the trial court should have dismissed the failure to recall claim because it was subsumed into the strict products liability count of plaintiff's complaint and preempted by the FDCA and its regulation, 21 C.F.R. §§ 7.40 to 7.59. It asserts FDA regulations for…”
15
GREENFisher Bros. Sales v. United States, 46 F.3d 279 (3d Cir. 1995).
cites § 7.40 2×cited by 1 caseunknown
Where it cites § 7.40
“21 C.F.R. § 7.40 (b). Thus, whether recall is warranted is assessed in light of "the degree of seriousness of the health hazard" and "the likelihood of occurrence of the hazard.”
16
NO FLAGWashington Cnty. Health Care Auth., Inc. v. Baxter Int'l Inc., No. 1:16-cv-10324 (N.D. Ill. July 5, 2018).
cites § 7.40 1×cited by 0 casesunknown
Where it cites § 7.40
“§ 331 (a) (prohibiting “the introduction or delivery for introduction into interstate commerce of any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded”); see also 21 C.F.R. § 7.40 (noting that “recall is an alternative to a Food and Drug…”
17
NO FLAGUnited States v. Pfizer, Inc., No. 1:16-cv-07142, 2019 WL 1200753 (N.D. Ill. Mar. 14, 2019).
cites § 7.40 1×cited by 0 casesunknown
Where it cites § 7.40
“Relator claims Hospira’s failure to inform the public and FDA about the false alarm and dosage problems, and its subsequent decision to characterize the software revisions as enhancements rather than corrections, constituted a silent recall in violation of FDA regulations, 21…”
18
NO FLAGALZA Corp. v. Doris Thompson, No. 13-07-00090-CV, 2010 WL 1254610 (Tex. App.—Corpus Christi Apr. 1, 2010).
cites § 7.40 1×subsections: (a)cited by 0 cases
Where it cites § 7.40
“21 C.F.R.§ 7.40(a) (2009). A recall is an “alternative” to a FDA-initiated court action, and the agency, by setting forth specific procedures, can “m onitor recalls and assess the adequacy of a firm ’s efforts in recall.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198120022024

One bar per year. Tallest: 2 cases in 2008. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.N.J.3N.D. Cal.2N.D. Ill.21st Cir.13rd Cir.14th Cir.18th Cir.1E.D. Ill.1

The 8 courts with the most citing cases, of 14 courts in all.

By subsection
(a)1 case
ALZA Corp. v. Doris Thompson, No. 13-07-00090-CV, 2010 WL 1254610 (Tex. App.—Corpus Christi Apr. 1, 2010).“21 C.F.R.§ 7.40(a) (2009). A recall is an “alternative” to a FDA-initiated court action, and the agency, by setting forth specific procedures, can “m onitor recalls and assess the adequacy of a firm ’s efforts in recall.”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com